SEOUL - South Korea's Celltrion Inc said on Monday its experimental treatment of Covid-19 demonstrated a 100-fold reduction in viral load of the disease in animal testing.
The pre-clinical study of the drug showed improved recovery in runny nose, cough and body aches after the first day of treatment, and clearing of lung inflammation within six days, the company said in a statement.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: